Catalyst
Slingshot members are tracking this event:
Phase 2 data of Avexitide (Exendin 9-39) in Post-Bariatric Hypoglycemia (PBH) to be presented at ENDO March 25, 2019.
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| EIGR | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 25, 2019
Occurred Source:
http://ir.eigerbio.com/phoenix.zhtml?c=254349&p=irol-newsArticle&ID=2392236
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Avexitide, Xendin 9-39, Post-bariatric Hypoglycemia
